mHealth to Increase Measles Immunization - a Randomized Controlled Trial in Guinea-Bissau (mimi)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02662595|
Recruitment Status : Unknown
Verified January 2016 by Bandim Health Project.
Recruitment status was: Not yet recruiting
First Posted : January 25, 2016
Last Update Posted : January 25, 2016
The question that this project seeks to answer, is whether mobile phones can be used to increase the measles vaccination coverage and timeliness in Guinea-Bissau. The intervention will be evaluated in terms of direct health outcomes and cost/benefit analysis, generating evidence that could help policy makers making informed decisions about implementing mHealth interventions at a national level.
The intervention takes the form of a randomized controlled trial in which text messages (SMS) as well as voice calls are scheduled and delivered to mo thers to remind and encourage them to have their children timely vaccinated against measles. In addition, the messages will include relevant information about opening hours and availability of the measles vaccine at the mothers' local health facilities thus improving coordination. The trial will include three different randomization groups with approx. 350 participants in each group. The first group will receive SMS messages, the second group will receive a voice call in addition to the SMS messages, and the third group is a control group that does not receive any intervention.
Study participants will be enrolled following birth at one of three health centers in different rural regions of Guinea-Bissau. Before the measles vaccine is scheduled to be given, at 9 months of age, mothers will receive the intervention message depending on their assigned randomization group. When the measles vaccine is administered, the child will be registered as having received the measles vaccination.
A follow-up phone interview will be conducted at 12 months of age for all children participating regardless of randomization group and whether or not they received the measles vaccine. All participating children, who at that time still have not received the measles vaccine, will be offered the vaccine at the expense of the project.
|Condition or disease||Intervention/treatment||Phase|
|Measles||Other: SMS reminder message Other: Voice call + SMS message||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||1050 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Care Provider, Investigator)|
|Primary Purpose:||Health Services Research|
|Official Title:||Mimi - mHealth to Increase Measles Immunization. A Randomized Controlled Trial.|
|Study Start Date :||March 2016|
|Estimated Primary Completion Date :||January 2018|
|Estimated Study Completion Date :||January 2018|
|No Intervention: Control|
Active Comparator: Text message
Subjects in this arm will receive a text message reminder in due time for measles vaccination.
Other: SMS reminder message
Active Comparator: Text message and voice call
Subjects in this arm will receive a voice call in addition to a text message reminder in due time for measles vaccination.
Other: Voice call + SMS message
- MV Coverage at 12 months of age [ Time Frame: 12 months of age ]Difference in measles vaccination coverage at 12 months of age between the intervention and the control groups.
- Timeliness [ Time Frame: At 12 months ]Difference in timeliness of measles vaccines administered, measured as median age of measles vaccinated children.
- Average number of visits [ Time Frame: At 12 months ]Average number of visits to the health center with the purpose of receiving MV needed before MV is successfully administered.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02662595
|Contact: Emil Rossing, MAfirstname.lastname@example.org|
|Contact: Amabélia Rodrigues, Dr.||email@example.com|
|Varela Health Center||Not yet recruiting|
|Varela, Cacheu, Guinea-Bissau|
|Paunca Health Center||Not yet recruiting|
|Paunca, Gabú, Guinea-Bissau|
|Catio Health Center||Not yet recruiting|
|Catío, Tombali, Guinea-Bissau|